Lapierre Ariane, Bourillon Laura, Larroque Marion, Gouveia Tiphany, Bourgier Céline, Ozsahin Mahmut, Pèlegrin André, Azria David, Brengues Muriel
IRCM, INSERM, University Montpellier, ICM, 34298 Montpellier, France.
Department of Radiotherapy-Oncology, Lyon-Sud Hospital Center, 69310 Pierre-Bénite, France.
Cancers (Basel). 2022 Apr 22;14(9):2097. doi: 10.3390/cancers14092097.
Personalized treatment and precision medicine have become the new standard of care in oncology and radiotherapy. Because treatment outcomes have considerably improved over the last few years, permanent side-effects are becoming an increasingly significant issue for cancer survivors. Five to ten percent of patients will develop severe late toxicity after radiotherapy. Identifying these patients before treatment start would allow for treatment adaptation to minimize definitive side effects that could impair their long-term quality of life. Over the last decades, several tests and biomarkers have been developed to identify these patients. However, out of these, only the Radiation-Induced Lymphocyte Apoptosis (RILA) assay has been prospectively validated in multi-center cohorts. This test, based on a simple blood draught, has been shown to be correlated with late radiation-induced toxicity in breast, prostate, cervical and head and neck cancer. It could therefore greatly improve decision making in precision radiation oncology. This literature review summarizes the development and bases of this assay, as well as its clinical results and compares its results to the other available assays.
个性化治疗和精准医学已成为肿瘤学和放射治疗的新护理标准。由于在过去几年中治疗效果有了显著改善，永久性副作用正日益成为癌症幸存者的一个重大问题。5%至10%的患者在放疗后会出现严重的晚期毒性反应。在治疗开始前识别出这些患者将有助于调整治疗方案，以尽量减少可能损害其长期生活质量的确定性副作用。在过去几十年中，已经开发了几种检测方法和生物标志物来识别这些患者。然而，其中只有辐射诱导淋巴细胞凋亡（RILA）检测在多中心队列中得到了前瞻性验证。这项基于简单采血的检测已被证明与乳腺癌、前列腺癌、宫颈癌以及头颈癌的晚期辐射诱导毒性相关。因此，它可以极大地改善精准放射肿瘤学中的决策制定。这篇文献综述总结了该检测方法的发展、基础及其临床结果，并将其结果与其他可用检测方法进行了比较。
